A systematic review of the effectiveness of adalimumab
A systematic review of the effectiveness of adalimumab
A systematic review of the effectiveness of adalimumab
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
52<br />
Effectiveness<br />
Review: Etanercept for rheumatoid arthritis 2006<br />
Comparison: 01 Etanercept s.c. licensed dose only (25 mg twice weekly or 50 mg once weekly) vs placebo, end <strong>of</strong> trial<br />
Outcome: 07 SAEs<br />
Study<br />
or subcategory<br />
Etanercept<br />
n/N<br />
Control<br />
n/N<br />
01 With (+) or without (–) concurrent, ongoing conventional DMARDs<br />
Moreland, 1999122 [26 weeks] (–)<br />
Keystone, 2004129 [8 weeks] (±)<br />
Baumgartner, 2004104 [20 weeks] (±)<br />
Weinblatt, 1999125 [24 weeks] (+)<br />
Codreanu, 2003103 [24 weeks] (+)<br />
Subtotal (95% CI)<br />
Total events: 37 (etanercept), 23 (control)<br />
Test for heterogeneity: 2 = 3.27, df = 4 (p = 0.51), I2 2/78<br />
5/367<br />
23/266<br />
2/59<br />
5/101<br />
3/80<br />
0/53<br />
16/269<br />
3/30<br />
1/50<br />
871 482<br />
= 0%<br />
Test for overall effect: z = 0.95 (p = 0.34)<br />
02 With concurrent, newly initiated MTX (etanercept + MTX)<br />
TEMPO 110 [104 weeks] (+)<br />
Subtotal (95% CI)<br />
Total events: 52 (etanercept), 41 (control)<br />
Test for heterogeneity: NA<br />
Test for overall effect: z = 1.21 (p = 0.23)<br />
52/231 41/228<br />
231 228<br />
Total (95% CI)<br />
Total events: 89 (etanercept), 64 (control)<br />
Test for heterogeneity: 2 = 4.55, df = 5 (p = 0.47), I2 1102 710<br />
= 0%<br />
Test for overall effect: z = 1.54 (p = 0.12)<br />
RD (fixed)<br />
95% CI<br />
–0.5 –0.25 0 0.25 0.5<br />
Favours etanercept Favours control<br />
Weight<br />
%<br />
10.19<br />
11.95<br />
34.50<br />
5.13<br />
8.63<br />
70.40<br />
29.60<br />
29.60<br />
100.00<br />
FIGURE 32 SAE RD: etanercept licensed dose only versus placebo (including etanercept plus MTX versus MTX)<br />
Review: Etanercept for rheumatoid arthritis 2006<br />
Comparison: 01 Etanercept s.c. licensed dose only (25 mg twice weekly or 50 mg once weekly) vs placebo, end <strong>of</strong> trial<br />
Outcome: 09 Malignancy<br />
Study<br />
or subcategory<br />
Etanercept<br />
n/N<br />
Control<br />
n/N<br />
01 With (+) or without (–) concurrent, ongoing conventional DMARDs<br />
Wadjula, 2000126 [12 weeks] (–)<br />
Moreland, 1999122 [26 weeks] (–)<br />
Keystone, 2004129 [8 weeks] (±)<br />
Baumgartner, 2004104 [20 weeks] (±)<br />
Weinblatt, 1999125 [24 weeks] (+)<br />
Codreanu, 2003103 [24 weeks] (+)<br />
Subtotal (95% CI)<br />
Total events: 2 (etanercept), 5 (control)<br />
Test for heterogeneity: 2 = 0.60, df = 2 (p = 0.74), I2 0/111<br />
0/78<br />
0/367<br />
2/266<br />
0/59<br />
0/101<br />
1/105<br />
0/80<br />
0/53<br />
3/269<br />
1/30<br />
0/50<br />
982 587<br />
= 0%<br />
Test for overall effect: z = 1.21 (p = 0.23)<br />
02 With concurrent, newly initiated MTX (etanercept + MTX)<br />
TEMPO 110 [104 weeks] (+)<br />
Subtotal (95% CI)<br />
Total events: 5 (etanercept), 2 (control)<br />
Test for heterogeneity: NA<br />
Test for overall effect: z = 1.09 (p = 0.28)<br />
5/231 2/228<br />
231 228<br />
Total (95% CI)<br />
Total events: 7 (etanercept), 7 (control)<br />
Test for heterogeneity: 2 = 30.3, df = 3 (p = 0.39), I2 1213 815<br />
= 1.0%<br />
Test for overall effect: z = 0.18 (p = 0.86)<br />
RR (fixed)<br />
95% CI<br />
0.01 0.1 1 10 100<br />
Favours etanercept Favours control<br />
Weight<br />
%<br />
FIGURE 33 Malignancy RR: etanercept licensed dose only versus placebo (including etanercept plus MTX versus MTX)<br />
18.10<br />
35.03<br />
23.23<br />
76.36<br />
23.64<br />
23.64<br />
100.00<br />
RD (fixed)<br />
95% CI<br />
–0.01 (–0.07 to 0.04)<br />
0.01 (–0.01 to 0.04)<br />
0.03 (–0.02 to 0.07)<br />
–0.07 (–0.18 to 0.05)<br />
0.03 (–0.03 to 0.09)<br />
0.01 (–0.01 to 0.04)<br />
0.05 (–0.03 to 0.12)<br />
0.05 (–0.03 to 0.12)<br />
0.02 (–0.01 to 0.05)<br />
RR (fixed)<br />
95% CI<br />
0.32 (0.01 to 7.66)<br />
Not estimable<br />
Not estimable<br />
0.67 (0.11 to 4.00)<br />
0.17 (0.01 to 4.10)<br />
Not estimable<br />
0.44 (0.11 to 1.68)<br />
2.47 (0.48 to 12.59)<br />
2.47 (0.48 to 12.59)<br />
0.92 (0.35 to 2.37)